Earnings Summary

Summit Therapeutics Inc’s net profit fell -123.99% since last year same period to $-36.57Mn in the Q1 2024. On a quarterly growth basis, Summit Therapeutics Inc has generated -71.93% fall in its net profits since last 3-months.

Summit Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.26 - a 0% jump from last quarter’s estimates.

Summit Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.26.

Summit Therapeutics Inc’s earning per share (EPS) jumped 42.86% since last year same period to -0.04 in the Q1 2024. This indicates that the Summit Therapeutics Inc has generated 42.86% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Summit Therapeutics Inc’s return on assets (ROA) stands at -0.13.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Summit Therapeutics Inc’s return on equity (ROE) stands at -6.02.